See more : IOU Financial Inc. (IOUFF) Income Statement Analysis – Financial Results
Complete financial analysis of Genkyotex SA (GKTX.PA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genkyotex SA, a leading company in the Biotechnology industry within the Healthcare sector.
- P.T. Bank Pan Indonesia Tbk (PNBN.JK) Income Statement Analysis – Financial Results
- Novo Resources Corp. (NVOOF) Income Statement Analysis – Financial Results
- Sixty North Gold Mining Ltd. (SXNTF) Income Statement Analysis – Financial Results
- Crown Cap Ventures Ltd. (CCVL) Income Statement Analysis – Financial Results
- Energem Corp. (ENCP) Income Statement Analysis – Financial Results
Genkyotex SA (GKTX.PA)
About Genkyotex SA
Genkyotex SA, a biopharmaceutical company, develops oral small molecule NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit NOX enzymes amplifying various disease processes, such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company's lead product candidate is GKT831, a NOX1 and NOX4 inhibitor, which is evaluated in a Phase II clinical trial in primary biliary cholangitis a fibrotic orphan disease and in an investigator-initiated Phase II clinical trial in type 1 diabetes and kidney disease. Its preclinical stage product candidate is GKT771, a NOX1 inhibitor targeting various pathways in pain processing and inflammation. Genkyotex SA has a license agreement with Serum Institute of India Ltd. for GTL003, an antigen for use in the development of acellular multivalent combination vaccines against a variety of infectious diseases. The company was founded in 2006 and is headquartered in Labège, France.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 794.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 794.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 11.68M | 3.99M | 9.28M | 9.48M | 7.18M | 10.94M | 10.79M | 6.91M | 5.37M | 5.46M |
| General & Administrative | 1.78M | 1.36M | 1.97M | 2.42M | 1.49M | 2.18M | 1.24M | 617.97K | 464.46K | 466.01K |
| Selling & Marketing | 183.00K | 89.00K | 0.00 | 142.00K | 79.72K | 121.75K | 82.55K | 7.63K | 17.59K | 10.85K |
| SG&A | 1.97M | 1.45M | 1.97M | 2.56M | 1.57M | 2.31M | 1.32M | 625.60K | 482.05K | 476.86K |
| Other Expenses | 413.00K | 1.98M | -22.00K | 2.07M | -3.76M | -1.82M | -1.56M | -1.49M | -475.08K | -724.61K |
| Operating Expenses | 14.06M | 7.43M | 11.23M | 14.10M | 4.99M | 11.42M | 10.56M | 6.05M | 5.38M | 5.21M |
| Cost & Expenses | 14.06M | 7.43M | 11.23M | 14.10M | 4.99M | 11.42M | 10.56M | 6.05M | 5.38M | 5.21M |
| Interest Income | 0.00 | 64.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 85.80K | 15.20K | 52.80K |
| Interest Expense | 75.00K | 156.00K | 1.15M | 0.00 | 0.00 | 0.00 | 0.00 | 64.62K | 289.37K | 44.52K |
| Depreciation & Amortization | 619.00K | 714.00K | 591.00K | 515.00K | 72.57K | 55.96K | 35.25K | 49.18K | 87.40K | 129.50K |
| EBITDA | -13.37M | -6.33M | -9.67M | -25.25M | -7.17M | -11.14M | -10.63M | -5.85M | -5.28M | -5.03M |
| EBITDA Ratio | 0.00% | 0.00% | -1,218.39% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -13.99M | -7.05M | -10.27M | -25.77M | -7.24M | -11.19M | -10.67M | -5.90M | -5.36M | -5.16M |
| Operating Income Ratio | 0.00% | 0.00% | -1,292.82% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -75.00K | -156.00K | -1.15M | 0.00 | 0.00 | 0.00 | 0.00 | -64.62K | -289.37K | -44.52K |
| Income Before Tax | -14.06M | -7.20M | -11.42M | -25.77M | -7.24M | -11.19M | -10.67M | -5.96M | -5.65M | -5.20M |
| Income Before Tax Ratio | 0.00% | 0.00% | -1,437.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 75.00K | 156.00K | 1.15M | 5.00K | 0.00 | 0.00 | 0.00 | 64.62K | 289.37K | 44.52K |
| Net Income | -14.14M | -7.36M | -12.57M | -25.77M | -7.24M | -11.19M | -10.67M | -6.03M | -5.94M | -5.24M |
| Net Income Ratio | 0.00% | 0.00% | -1,583.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.20 | -0.86 | -1.53 | -3.72 | -4.44 | -6.90 | -7.37 | -31.21 | -30.78 | -27.16 |
| EPS Diluted | -1.20 | -0.86 | -1.53 | -3.72 | -4.44 | -6.90 | -7.37 | -31.21 | -30.78 | -27.16 |
| Weighted Avg Shares Out | 11.79M | 8.55M | 8.19M | 6.93M | 1.63M | 1.62M | 1.45M | 193.09K | 193.09K | 193.09K |
| Weighted Avg Shares Out (Dil) | 11.79M | 8.55M | 8.19M | 6.93M | 1.63M | 1.62M | 1.45M | 193.09K | 193.09K | 193.09K |
Source: https://incomestatements.info
Category: Stock Reports